Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Assertio Therapeutics Inc (ASRT)

Assertio Therapeutics Inc (ASRT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 98,536
  • Shares Outstanding, K 64,826
  • Annual Sales, $ 311,770 K
  • Annual Income, $ 36,910 K
  • 60-Month Beta 1.92
  • Price/Sales 0.32
  • Price/Cash Flow 0.59
  • Price/Book 0.50

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.21
  • Number of Estimates 1
  • High Estimate -0.21
  • Low Estimate -0.21
  • Prior Year 0.65
  • Growth Rate Est. (year over year) -132.31%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.27 +19.69%
on 08/20/19
3.55 -57.18%
on 07/30/19
-1.53 (-50.16%)
since 07/22/19
3-Month
1.27 +19.69%
on 08/20/19
3.63 -58.13%
on 06/28/19
-1.91 (-55.69%)
since 05/22/19
52-Week
1.27 +19.69%
on 08/20/19
7.43 -79.54%
on 08/28/18
-5.72 (-79.01%)
since 08/22/18

Most Recent Stories

More News
Assertio Therapeutics Enters Oversold Territory

Assertio Therapeutics has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

ASRT : 1.52 (-0.65%)
ASRT vs. PCRX: Which Stock Is the Better Value Option?

ASRT vs. PCRX: Which Stock Is the Better Value Option?

ASRT : 1.52 (-0.65%)
PCRX : 37.94 (-3.66%)
Assertio Therapeutics Announces Exchange Offer of $200 Million of its Currently Outstanding 2.50% Convertible Notes Due 2021

Assertio Therapeutics, Inc. (NASDAQ: ASRT) ("Assertio") today announced it has entered into separate, privately negotiated exchange agreements (the "Exchange Agreements") with a limited number of holders...

ASRT : 1.52 (-0.65%)
Assertio (ASRT) Q2 Earnings Beat Estimates

Assertio (ASRT) delivered earnings and revenue surprises of 8.70% and -2.20%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

ASRT : 1.52 (-0.65%)
ASRT or AMRX: Which Is the Better Value Stock Right Now?

ASRT vs. AMRX: Which Stock Is the Better Value Option?

ASRT : 1.52 (-0.65%)
AMRX : 2.68 (-3.60%)
Assertio Therapeutics to Report Second Quarter 2019 Financial Results After The Close of Markets on Wednesday, August 7, 2019

Assertio Therapeutics, Inc. (NASDAQ:ASRT) today announced that it will release second quarter 2019 financial results on Wednesday, August 7, 2019, after the close of markets. Following the announcement,...

ASRT : 1.52 (-0.65%)
La Jolla (LJPC) Secures Positive CHMP Opinion for Giapreza

The CHMP recommends La Jolla's (LJPC) marketing application for Giapreza to treat refractory hypotension in adult patients with septic or distributive shock.

LJPC : 10.22 (-0.87%)
ASRT : 1.52 (-0.65%)
SLNO : 1.88 (-4.92%)
EVTCY : 43.4700 (-2.66%)
BioCryst Down Despite Hereditary Angioedema Study Meets Goal

BioCryst's (BCRX) phase III study on BCX7353 for the prevention of hereditary angioedema attacks meets the primary endpoint for both doses (110mg/150 mg). Shares depreciate despite this upside.

JAZZ : 130.82 (-2.26%)
BCRX : 2.57 (-3.75%)
ASRT : 1.52 (-0.65%)
BLRX : 3.09 (-0.32%)
ASSERTIO THERAPEUTICS Enters Oversold Territory

ASSERTIO THERAPEUTICS has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

ASRT : 1.52 (-0.65%)
Is ASSERTIO THERAPEUTICS, INC (ASRT) Stock Outpacing Its Medical Peers This Year?

Is (ASRT) Outperforming Other Medical Stocks This Year?

ASRT : 1.52 (-0.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade ASRT with:

Business Summary

Assertio Therapeutics, Inc. is a pharmaceutical company. It develops and markets a product for the treatment in neurology, orphan and diseases of the central nervous system. Assertio Therapeutics, Inc., formerly known as Depomed Inc., is headquartered in Lake Forest, Illinois.

See More

Key Turning Points

2nd Resistance Point 1.63
1st Resistance Point 1.57
Last Price 1.52
1st Support Level 1.44
2nd Support Level 1.37

See More

52-Week High 7.43
Fibonacci 61.8% 5.08
Fibonacci 50% 4.35
Fibonacci 38.2% 3.62
Last Price 1.52
52-Week Low 1.27

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar